Forward P/S Multiple: Accelerate Diagnostics (AXDX)

Brandmark of Accelerate Diagnostics, Inc. (AXDX)

Logistics challenges regarding reagents and contract electronics manufacturing are creating volatility reflected in the modeled P/S of Accelerate Diagnostics (AXDX), where the metric remains around 0.10. Accelerate Diagnostics (AXDX) is addressing this by developing rapid tests for sepsis diagnostics in clinics. The optimization of housing component production processes and final system calibration allow the business to minimize risks associated with dependence on external suppliers.

Accelerate Diagnostics, Inc. - AXDX Market Cap to Future Revenue Ratio (period 07/04/2022 - 05/24/2025)

AXDX (Accelerate Diagnostics Inc): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Accelerate Diagnostics, Inc.|AXDX - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Accelerate Diagnostics Inc|AXDX - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Value per Share Accelerate Diagnostics|AXDX - Total Stockholders' Equity|Market Value to Book Value Ratio acceleratediagnostics.com|AXDX - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Accelerate Diagnostics|AXDX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Accelerate Diagnostics|AXDX - Aggregate Debt Obligations|Debts to Book Capitalization Accelerate Diagnostics Inc|AXDX - Company Long-Term Debts|Company Current Liabilities Accelerate Diagnostics|Quick Ratio acceleratediagnostics.com
- financial results and valuation multiples details:
AXDX - Company Net Income|Future Profit Accelerate Diagnostics|AXDX - Company Value to Net Income|Forward P/E Multiple Accelerate Diagnostics, Inc|AXDX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Accelerate Diagnostics Inc|AXDX - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Accelerate Diagnostics|AXDX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth acceleratediagnostics.com|AXDX - Net earnings per share change in current year|Net earnings per share growth forecast for next year Accelerate Diagnostics
- revenue and sales details:
AXDX - Company Sales Volume|Company Projected Revenue Accelerate Diagnostics, Inc.|AXDX - Price to Sales|Price-to-Projected Revenue Ratio Accelerate Diagnostics Inc
Summary company analysis:Accelerate Diagnostics, Inc. AXDX
Product sample of Accelerate Diagnostics

Finding a balance between return on capital and the risks of slow adoption for costly diagnostic systems requires an assessment of market expectations regarding future revenue streams. Analyzing the forward P/S chart, an investor compares the current market capitalization of Accelerate Diagnostics (AXDX) with projected turnover, which is critical for a loss-making business facing fierce competition from medtech behemoths and the threat of a correction if valuations are inflated.

Competitors of Accelerate Diagnostics

Forward P/S Multiple A (Agilent)|DGX - Forward Price-to-Revenue Multiple|Illumina Corp - Forward P/S Multiple|Exact Sciences Inc. (EXAS) - Forward Price-to-Revenue Multiple|RVTY: Forward P/S Multiple|Market Cap to Future Revenue Ratio bio-rad.com (BIO)|Price-to-Projected Revenue Ratio Anbio|Price-to-Projected Revenue Ratio SHC|Forward P/S Multiple QDEL|OPK - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio CareDx, Inc CDNA|Forward Price to Sales MRVI|Fulgent Genetics - Forward P/S Multiple|LAB - Forward P/S Multiple|CTKB (Cytek Bio) - Forward Price-to-Revenue Multiple|OSUR: Price to Expected Revenue Ratio|XGN (Exagen Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio mdxhealth.com MDXH|Forward Price-to-Revenue Multiple LUCD (Lucid Diagnostics)|PRE (prenetics.com) - Forward Price to Sales|Forward P/S Multiple IMDX (Insight Molecular Diagnostics Inc)|TRIB: Market Cap to Projected Revenue|ProPhase Labs, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio ainos.com AIMD|CODX: Forward P/S Multiple|Heart Test Laboratories, Inc. (HSCS) - Forward P/S Multiple|BMRA (Biomerica, Inc) - Forward P/S Multiple|CDIO - Projected Price to Revenue|Price-to-Projected Revenue Ratio Onconetix, Inc. (ONCO)|viraxbiolabs.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Bluejay Diagnostics, Inc. BJDX|Aspira Women's Health, Inc. (AWH) - Market Cap to Future Revenue Ratio|CNTG - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Enzo Biochem, Inc. ENZ|FRES (fresh2.co) - Forward Price-to-Revenue Multiple|GENE: Price to Expected Revenue Ratio|ME (23andMe) - Forward P/S Multiple|Psychemedics Corp. (PMD) - Market Cap to Expected Sales Ratio